Paradigm Biopharmaceuticals Limited (ASX: PAR) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Paradigm Biopharmaceuticals Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Paradigm Biopharmaceuticals Limited (ASX: PAR)
Latest News
Share Market News
Why this ASX healthcare share has risen over 200% in the past year
Share Gainers
Why these All Ords shares have doubled in value in 12 months
Healthcare Shares
Why Paradigm Biopharmaceuticals is one to watch in 2020
Share Market News
These 3 ASX healthcare shares could make you rich
Share Fallers
Paradigm share price tumbles lower on FDA update
Share Market News
Paradigm Biopharmaceuticals shares lower despite US update
Share Market News
Leading brokers name 3 ASX shares to sell today
Share Market News
Paradigm Biopharmaceuticals shares have skyrocketed. Should you invest?
Share Market News
Why this growing ASX healthcare company should be on everyone's watch lists
52-Week Highs
Why these ASX shares just raced to 52-week highs or better
Growth Shares
I would buy Zip Co and these ASX mid cap stars in February
How to invest
Are these the millionaire maker ASX shares of the 2020s?
Frequently Asked Questions
-
No, Paradigm does not pay shareholder dividends at this time.
-
Paradigm Biopharmaceuticals Limited listed on the ASX on 19 August 2015.
PAR ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Paradigm Biopharmaceuticals Limited
Paradigm Biopharmaceuticals Ltd (ASX: PAR) is a late-stage drug development company researching drug repurposing. The company seeks to identify and transform existing molecules to develop effective treatments for conditions with limited treatment options. Currently, more than 30% of therapies approved or launched globally represent drugs approved for new indications, reformulations, or new combinations of existing drugs.
Paradigm's current commercial prospect is injectable pentosan polysulfate sodium (PPS, or brand name Zilosul®) in the treatment of osteoarthritis. PPS is FDA-approved and has a track record of treating inflammation including bladder condition cystitis and is used in the EU for preventing deep vein thrombosis. Paradigm has advanced to Phase 3 trial stage investigating PPS for osteoarthritis treatment. The company is based in Melbourne with offices in the US and Europe.
